PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 1986New England Journal of Medicine364 citations

Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor Antibody

View Full Paper
SCSarah ClarksonJBJames B. BusselRKRobert P. Kimberly

Key Points

Key points are not available for this paper at this time.

Abstract

THE production of antiplatelet antibodies and removal of IgG-coated platelets by the mononuclear phagocyte system play an important part in the pathogenesis of immune thrombocytopenic purpura. The coating of platelets with immunoglobulin results in their removal in the spleen and liver, presumably by receptors for the Fc fragment of IgG (Fcγ).1 , 2 Prolongation of Fcγ-receptor-mediated clearance of opsonized red cells after splenectomy1 , 3 and infusions of high doses of intravenous gamma globulin,4 , 5 in conjunction with favorable clinical responses to these therapies, support this hypothesis. Some patients, however, respond to neither of these treatments nor to other, less specific forms of immunosuppression, such . . .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Clarkson et al. (1986) studied this question.

synapsesocial.com/papers/6a1fb6640ce5b02b0aa074a9https://doi.org/10.1056/nejm198605083141907
Ask AI
Helpful
Bookmark
Share
View Full Paper